SI1750683T1 - Formulacije s podaljĺ anim sproĺ äśanjem - Google Patents

Formulacije s podaljĺ anim sproĺ äśanjem

Info

Publication number
SI1750683T1
SI1750683T1 SI200531678T SI200531678T SI1750683T1 SI 1750683 T1 SI1750683 T1 SI 1750683T1 SI 200531678 T SI200531678 T SI 200531678T SI 200531678 T SI200531678 T SI 200531678T SI 1750683 T1 SI1750683 T1 SI 1750683T1
Authority
SI
Slovenia
Prior art keywords
sustained release
release formulations
formulations
sustained
release
Prior art date
Application number
SI200531678T
Other languages
English (en)
Slovenian (sl)
Inventor
Merrill S. Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc. M/S 27-4-A, Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. M/S 27-4-A, Amgen Inc. filed Critical Amgen Inc. M/S 27-4-A, Amgen Inc.
Publication of SI1750683T1 publication Critical patent/SI1750683T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200531678T 2004-04-23 2005-04-25 Formulacije s podaljĺ anim sproĺ äśanjem SI1750683T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23
EP05742315A EP1750683B1 (en) 2004-04-23 2005-04-25 Sustained release formulations
PCT/US2005/014254 WO2005105057A1 (en) 2004-04-23 2005-04-25 Sustained release formulations

Publications (1)

Publication Number Publication Date
SI1750683T1 true SI1750683T1 (sl) 2013-04-30

Family

ID=34967842

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531678T SI1750683T1 (sl) 2004-04-23 2005-04-25 Formulacije s podaljĺ anim sproĺ äśanjem

Country Status (15)

Country Link
US (2) US7323169B2 (enExample)
EP (1) EP1750683B1 (enExample)
JP (3) JP5036533B2 (enExample)
KR (1) KR101201638B1 (enExample)
CN (2) CN1997356A (enExample)
AU (1) AU2005237542B2 (enExample)
CA (1) CA2563185C (enExample)
DK (1) DK1750683T3 (enExample)
ES (1) ES2400687T3 (enExample)
IL (1) IL178596A (enExample)
PL (1) PL1750683T3 (enExample)
PT (1) PT1750683E (enExample)
SI (1) SI1750683T1 (enExample)
WO (1) WO2005105057A1 (enExample)
ZA (1) ZA200609401B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997356A (zh) * 2004-04-23 2007-07-11 安姆根有限公司 持续释放制剂
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
MX2008001468A (es) * 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
AU2007237163A1 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
EP2498096A1 (en) * 2006-07-21 2012-09-12 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
JP2011513220A (ja) * 2008-02-21 2011-04-28 ヴァトリックス・メディカル・インコーポレーテッド デリバリービヒクルと組み合わせた結合組織安定剤の適用による動脈瘤の処置
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US9937255B2 (en) 2011-05-18 2018-04-10 Nectero Medical, Inc. Coated balloons for blood vessel stabilization
EP3907237A1 (en) 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US10941182B2 (en) 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
US11654114B2 (en) * 2017-06-07 2023-05-23 Egy-Nano Pharma, Lp Oral prolonged drug delivery platforms
EP3829664A4 (en) 2018-08-03 2022-05-04 Nectero Medical, Inc. PURIFIED PENTAGALLOYGLUCOSE AND DELIVERY DEVICES
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
CN119326891B (zh) * 2024-10-31 2025-07-01 中国人民解放军空军军医大学 Ei24激动剂以及在制备抑制食管鳞癌增殖的制剂的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
CH498653A (fr) 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
JP2001510788A (ja) * 1997-07-23 2001-08-07 ペリオ プロダクツ リミテッド 薬学的薬剤を薬学的に口腔内に制御放出するためのタンニン酸ポリマー組成物
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
AU766959B2 (en) * 1998-04-20 2003-10-30 Genzyme Corporation Drug delivery of proteins from polymeric blends
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
EP1225916A1 (en) 1999-11-01 2002-07-31 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
US6759064B2 (en) 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) * 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
AU2003254544A1 (en) * 2002-07-26 2004-02-23 Dsm Ip Assets B.V. Compositions comprising lactoferrin
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
CN1997356A (zh) * 2004-04-23 2007-07-11 安姆根有限公司 持续释放制剂

Also Published As

Publication number Publication date
WO2005105057A1 (en) 2005-11-10
AU2005237542A1 (en) 2005-11-10
JP2007534698A (ja) 2007-11-29
US7323169B2 (en) 2008-01-29
CN103920162B (zh) 2017-07-11
ZA200609401B (en) 2008-05-28
KR20070026457A (ko) 2007-03-08
JP5829870B2 (ja) 2015-12-09
JP2012036194A (ja) 2012-02-23
JP5036533B2 (ja) 2012-09-26
CA2563185C (en) 2010-04-20
US20050271722A1 (en) 2005-12-08
US7732399B2 (en) 2010-06-08
KR101201638B1 (ko) 2012-11-15
EP1750683B1 (en) 2013-01-09
IL178596A0 (en) 2007-02-11
IL178596A (en) 2012-06-28
HK1103023A1 (en) 2007-12-14
AU2005237542B2 (en) 2009-12-17
DK1750683T3 (da) 2013-04-15
US20070292506A1 (en) 2007-12-20
CN103920162A (zh) 2014-07-16
EP1750683A1 (en) 2007-02-14
JP2012046520A (ja) 2012-03-08
HK1200092A1 (en) 2015-07-31
CN1997356A (zh) 2007-07-11
PL1750683T3 (pl) 2013-05-31
ES2400687T3 (es) 2013-04-11
CA2563185A1 (en) 2005-11-10
PT1750683E (pt) 2013-01-25

Similar Documents

Publication Publication Date Title
IL184460A0 (en) Sustained release pharmaeutical formulations
IL178596A0 (en) Sustained release formulations
GB2424581B (en) Formulations
IL181265A0 (en) Stabilizing formulations
GB0406819D0 (en) Controlled release compositions
IL188964A0 (en) Sustained drug release composition
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
IL185773A0 (en) Formulations
HUE053838T2 (hu) Nyújtott felszabadulású nabulfin-készítmények
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
EP1951693A4 (en) SOLID FORMULATIONS
IL177328A0 (en) Controlled release formulations
GB0406048D0 (en) Drug formulations
IL179208A0 (en) Intereferon formulations
GB0417248D0 (en) Formulations
GB0417226D0 (en) Formulations
GB0426295D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations
GB0427249D0 (en) Novel formulations
GB0427244D0 (en) Novel formulations
GB0427245D0 (en) Novel formulations
GB0426296D0 (en) Novel formulations
GB0426294D0 (en) Novel formulations